BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.
Ilana MandelDana Haves ZivIlana GoldshteinTsuri PeretzDror AlishekevitzAnna Fridman DrorMotti HakimSharon HashmueliItay FriedmanYair SapirRita GrecoHongjing QuFrank NestleDmitri WiederschainLily PaoSharad K SharmaTehila Ben MoshePublished in: Journal for immunotherapy of cancer (2022)
NCT04717375.
Keyphrases